What Zoetis's FY2025 10-K says: 12 signals
Zoetis filed its latest 10-K with the SEC on Feb 12, 2026. It discusses capex increase, acquisition completed and AI investment.
Public (ZTS)Pharmaceutical Manufacturing10,000+ employeeszoetis.comLinkedIn
- Filed
- Feb 12, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 8
What Zoetis's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Zoetis makes multi-year AI investment in Vetscan Imagyst diagnostics platform from 2023-2025
Zoetis is continuously adding AI-powered capabilities to its Vetscan Imagyst platform, including dermatology, fecal, urine, and cell analysis.
AIartificial intelligenceimage recognition technologycloud-based AI
This acquisition significantly expands Zoetis's diagnostics footprint and service offerings in Europe.
Zoetis expanded its Vetscan Imagyst AI platform with new capabilities in 2024 and 2025.
Zoetis is heavily investing in its AI-powered diagnostics platform, adding AI urine sediment analysis in 2024 and AI Masses detection in 2025.
AIartificial intelligenceimage recognition technologyalgorithms
The acquisition of a multi-location veterinary diagnostic lab group will likely necessitate the integration of disparate Lab Information Management Systems (LIMS), ERPs, and CRM platforms.
Zoetis increasing investment in direct-to-consumer (DTC) marketing and sales channels
This pivot requires investment in e-commerce platforms, digital marketing automation, and customer data platforms (CDPs) to manage new customer relationships and sales funnels.
e-commerce
Zoetis partnered with Blacksmith Medicines in 2024 to develop novel antibiotics for animal health.
This collaboration aims to address the critical need for new antibiotics in livestock to treat life-threatening infections.
Blacksmith Medicines
The company received approvals for several key products in 2025, such as Lenivia and Portela for OA pain and a new label for Simparica Trio.
monoclonal antibody (mAb)
Acquired two R&D biopharma companies in 2023 to bolster antibody therapeutics pipeline
The acquisitions of PetMedix (U.K.) and adivo GmbH (Germany) represent a strategic capital allocation to enhance R&D capabilities, specifically in antibody-based therapies.
Showing 8 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Zoetis with the Signal API
One POST /v1/companies/enrich call with zoetis.com returns Zoetis 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zoetis.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Zoetis 10-K
When did Zoetis file its latest 10-K?
What does Zoetis's latest 10-K say about AI investment?
Where can I find Zoetis's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .